{
    "root": "7d2d3be8-5b23-4e66-be62-cfedd2dbccd7",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "ciprofloxacin",
    "value": "20250328",
    "ingredients": [
        {
            "name": "CIPROFLOXACIN HYDROCHLORIDE",
            "code": "4BA73M5E37"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CROSPOVIDONE",
            "code": "2S7830E561"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        }
    ],
    "indications": "ciprofloxacin fluoroquinolone antibacterial indicated adults ( 18 years age older ) following infections caused designated , susceptible bacteria pediatric patients indicated : skin skin structure infections ( 1.1 ) bone joint infections ( 1.2 ) complicated intra-abdominal infections ( 1.3 ) infectious diarrhea ( 1.4 ) typhoid fever ( enteric fever ) ( 1.5 ) uncomplicated cervical urethral gonorrhea ( 1.6 ) inhalational anthrax post-exposure adult pediatric patients ( 1.7 ) plague adult pediatric patients ( 1.8 ) chronic bacterial prostatitis ( 1.9 ) lower respiratory tract infections ( 1.10 ) acute exacerbation chronic bronchitis urinary tract infections ( 1.11 ) urinary tract infections ( uti ) acute uncomplicated cystitis complicated uti pyelonephritis pediatric patients acute sinusitis ( 1.12 ) usage reduce development drug-resistant bacteria maintain effectiveness ciprofloxacin antibacterial drugs , ciprofloxacin used treat prevent infections proven strongly suspected caused bacteria . ( 1.13 )",
    "contraindications": "ciprofloxacin tablets administered orally described appropriate guidelines tables .",
    "warningsAndPrecautions": "ciprofloxacin tablets usp 250 mg available white colored , biconvex , circular , film coated tablets , debossed ' p ' one side '250 ' side containing ciprofloxacin hydrochloride , usp equivalent 250 mg ciprofloxacin . ndc : 71335-0408-1 : 20 tablets bottle ndc : 71335-0408-2 : 10 tablets bottle ndc : 71335-0408-3 : 14 tablets bottle ndc : 71335-0408-4 : 6 tablets bottle ndc : 71335-0408-5 : 30 tablets bottle ndc : 71335-0408-6 : 60 tablets bottle ndc : 71335-0408-7 : 12 tablets bottle ndc : 71335-0408-8 : 40 tablets bottle ndc : 71335-0408-9 : 90 tablets bottle ndc : 71335-0408-0 : 7 tablets bottle store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0 f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0 f ) [ usp controlled room temperature ] . repackaged/relabeled : bryant ranch prepack , inc.burbank , ca 91504",
    "adverseReactions": "known hypersensitivity ciprofloxacin quinolones ( 4.1 , 5.6 , 5.7 ) concomitant tizanidine ( 4.2 )",
    "indications_original": "Ciprofloxacin is a fluoroquinolone antibacterial indicated in adults (18 years of age and older) with the following infections caused by designated, susceptible bacteria and in pediatric patients where indicated: Skin and Skin Structure Infections ( 1.1 ) Bone and Joint Infections ( 1.2 ) Complicated Intra-Abdominal Infections ( 1.3 ) Infectious Diarrhea ( 1.4 ) Typhoid Fever (Enteric Fever) ( 1.5 ) Uncomplicated Cervical and Urethral Gonorrhea ( 1.6 ) Inhalational Anthrax post-exposure in adult and pediatric patients ( 1.7 ) Plague in adult and pediatric patients ( 1.8 ) Chronic Bacterial Prostatitis ( 1.9 ) Lower Respiratory Tract Infections ( 1.10 ) o Acute Exacerbation of Chronic Bronchitis Urinary Tract Infections ( 1.11 ) o Urinary Tract Infections (UTI) o Acute Uncomplicated Cystitis o Complicated UTI and Pyelonephritis in Pediatric Patients Acute Sinusitis ( 1.12 ) Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of ciprofloxacin and other antibacterial drugs, ciprofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.13 )",
    "contraindications_original": "Ciprofloxacin tablets should be administered orally as described in the appropriate Dosage Guidelines tables.",
    "warningsAndPrecautions_original": "Ciprofloxacin tablets USP 250 mg are available as white colored, biconvex, circular, film coated tablets, debossed 'P' on one side and '250' on the other side containing ciprofloxacin hydrochloride, USP equivalent to 250 mg of ciprofloxacin.\n                  NDC: 71335-0408-1: 20 Tablets in a BOTTLE\n                  NDC: 71335-0408-2: 10 Tablets in a BOTTLE\n                  NDC: 71335-0408-3: 14 Tablets in a BOTTLE\n                  NDC: 71335-0408-4: 6 Tablets in a BOTTLE\n                  NDC: 71335-0408-5: 30 Tablets in a BOTTLE\n                  NDC: 71335-0408-6: 60 Tablets in a BOTTLE\n                  NDC: 71335-0408-7: 12 Tablets in a BOTTLE\n                  NDC: 71335-0408-8: 40 Tablets in a BOTTLE\n                  NDC: 71335-0408-9: 90 Tablets in a BOTTLE\n                  NDC: 71335-0408-0: 7 Tablets in a BOTTLE\n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0 F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0 F) [see USP Controlled Room Temperature].\n                  Repackaged/Relabeled by:Bryant Ranch Prepack, Inc.Burbank, CA 91504",
    "adverseReactions_original": "Known hypersensitivity to ciprofloxacin or other quinolones ( 4.1 , 5.6 , 5.7 ) Concomitant administration with tizanidine ( 4.2 )"
}